Ciclesonide
- Generic Name
- Ciclesonide
- Brand Names
- Alvesco, Omnaris, Zetonna
- Drug Type
- Small Molecule
- Chemical Formula
- C32H44O7
- CAS Number
- 126544-47-6
- Unique Ingredient Identifier
- S59502J185
- Background
Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.
- Indication
For the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older.
- Associated Conditions
- Asthma, Bronchoconstriction, Chronic Obstructive Pulmonary Disease (COPD), Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis
Effects of Inhaled Ciclesonide Versus Fluticasone Propionate Versus Placebo on Lower Leg Growth in Prepubertal Children With Mild Persistent Asthma (6 to 12 y) (BY9010/M1-208)
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2016-12-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT00163371
- Locations
- 🇩🇰
Altana Pharma/Nycomed, Kolding, Denmark
Effectiveness of Ciclesonide Versus Budesonide in Patients With Asthma (18 to 75 y) (BY9010/M1-136)
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 240
- Registration Number
- NCT00163384
- Locations
- 🇰🇷
Altana Pharma/Nycomed, Seoul, Korea, Republic of
Efficacy and Safety of Ciclesonide in Preschool Children With Asthma (2 to 6 Years) (BY9010/M1-207)
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2016-12-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT00163449
- Locations
- 🇨🇭
Altana Pharma/Nycomed, Zürich, Switzerland
Efficacy of Ciclesonide and Fluticasone Propionate in Adult Patients With Moderate and Severe Persistent Asthma (18 to 75 y) (BY9010/IT-101)
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 500
- Registration Number
- NCT00163319
- Locations
- 🇬🇧
Altana Pharma/Nycomed, Watford, United Kingdom
Effect of Inhaled Ciclesonide Versus Fluticasone Propionate in Patients With Mild to Moderate Asthma (18 to 65 y) (BY9010/M1-129)
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2016-12-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT00163332
- Locations
- 🇧🇪
Altana Pharma/Nycomed, Liége, Belgium
Efficacy of Ciclesonide Inhaled Once Daily Versus Fluticasone Propionate Inhaled Twice Daily in Children With Asthma (4 to 15 y) (BY9010/M1-205)
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 500
- Registration Number
- NCT00163410
- Locations
- 🇮🇳
Altana Pharma/Nycomed, Shastri Nagar, Jaipur, India
Efficacy of Ciclesonide Inhaled Once Daily Versus Other Corticosteroids Used for Treatment of Mild Asthma in Children (4 to 11 Years) (BY9010/CA-101)
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 240
- Registration Number
- NCT00163293
- Locations
- 🇿🇦
Altana Pharma/Nycomed, Kapstadt, South Africa
Efficacy of Ciclesonide Versus Fluticasone Propionate in Patients With Mild to Moderate Asthma (12 to 75 y) (BY9010/M1-142)
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2016-12-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 480
- Registration Number
- NCT00163423
- Locations
- 🇿🇦
Altana Pharma/Nycomed, Wynberg, South Africa
Efficacy of Ciclesonide on Small Airways in Patients With Stable Asthma (18 to 60 y) (BY9010/M1-131)
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2016-12-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT00163345
- Locations
- 🇳🇱
Altana Pharma/Nycomed, RB Groningen, Netherlands
Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)
Phase 3
Completed
- Conditions
- Hay FeverPerennial Allergic RhinitisAllergic Rhinitis
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 636
- Registration Number
- NCT00163514
- Locations
- 🇨🇦
Altana Pharma/Nycomed, Winnipeg, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath